1. OI-1
    EXPOSURE RESPONSE ANALYSIS AS EVIDENCE FOR APPROVAL OF CANAGLIFLOZIN-METFORMIN IMMEDIATE RELEASE FIXED-DOSE COMBINATION PRODUCT: A REGULATORY PERSPECTIVE.
  2. OI-2
    MARS (META-ANALYSIS USING R SHINY): A BROWSER BASED META-ANALYSIS MODELING VISUALIZATION APPLICATION.
  3. OI-3
    USE OF MODELING AND SIMULATION TO SUPPORT NALOXEGOL CLINICAL DEVELOPMENT AND SUBMISSION.
  4. OI-4
    IPX066 DOSE-RESPONSE IN PATIENTS WITH EARLY PARKINSON’S DISEASE USING A DELAYED START STUDY DESIGN.
  5. OII-1
    PREDICTIVE PERFORMANCE OF PHYSIOLOGICALLY BASED PHARMACOKINETC (PBPK) MODELS FOR THE EFFECT OF CYP 3A INDUCERS ON SUBSTRATE DRUGS: ANALYSIS OF SUBMISSIONS TO THE FDA.
  6. OII-2
    QUANTITATIVE MECHANISTIC STATIC MODEL FOR THE PREDICTION OF HUMAN RENAL ORGANIC ANION TRANSPORTER (OAT)-MEDIATED DRUG INTERACTIONS.
  7. OII-3
    EXPERIENCES WITH CONCENTRATION-EFFECT MODELING OF QT PROLONGATION.
  8. OII-4
    RITONAVIR IS THE BEST ALTERNATIVE TO KETOCONAZOLE AS AN INDEX CYP3A INHIBITOR.
  9. OIII-1
    INTEGRATING METABOLOMICS AND GENOMICS REVEALS NOVEL BIOMARKERS OF HYDROCHLOROTHIAZIDE RESPONSE IN PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES (PEAR) STUDY.
  10. OIII-2
    PERSONALIZED THERAPY FOR H. PYLORI INFECTION.
  11. OIII-3
    PERSONALIZED THIOPURINE DOSING BASED ON TPMT GENOTYPING REDUCES LEUCOPENIA OCCURRENCE AND RESULTS IN COST-SAVINGS IN IBD PATIENTS; A RANDOMIZED TRIAL IN THE NETHERLANDS.
  12. OIII-4
    CHARACTERIZATION OF THE RELATIONSHIP BETWEEN BIOMARKERS OF CYTOCHROME P450-MEDIATED EICOSANOID METABOLISM AND CORONARY ARTERY DISEASE SEVERITY IN HUMANS.